Special Issue "Metabolic Syndrome and COVID-19"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "SARS-CoV-2 and COVID-19".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editor

Dr. Eric Piver
E-Mail Website
Guest Editor
INSERM U1259, University of Tours, 37000 Tours, France
Biochemistry and Molecular Biology, Tours University Hospital, 3700 Tours, France
Interests: HIV-1; lipids; phosphoinositides

Special Issue Information

Dear Colleagues

During the replication of the Severe Acute Respiratory Coronavirus-2 (SARS-Cov2), some cellular pathways involving metabolites and lipids are dysregulated. A high level of inflammation is evidenced by high serum concentrations of C-reactive protein (CRP) or interleukin (IL)6, which are associated with the so-called cytokine storm in SARS-Cov2-infected patients. The mechanisms underlying the clinical severity of this infection have not been completely determined. However, some comorbidities such as Metabolic Syndrome (MetS) have been reported as associated with complications and mortality in SARS-Cov2-infected patients. MetS is defined by the World Health Organization (WHO) as a pathologic state determined by abdominal obesity, high body mass index (BMI), insulin resistance, hyperlipidemia, and hypertension. One of the hypotheses explaining the link between MetS and SARS-Cov2 infection (causing coronavirus disease 2019 (COVID-19)) is based on the low-grade inflammation largely reported in MetS patients, but other mechanisms could also be involved, like modification of angiotensin-converting enzyme 2 (ACE2) metabolism.

The purpose of this Special Issue is to highlight the links between MetS and severe forms of COVID-19, in both in vitro models and cohorts of patients.

Dr. Eric Piver
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • metabolic syndrome
  • severity of COVID-19
  • physiopathology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Brief Report
Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis
Viruses 2021, 13(10), 1938; https://0-doi-org.brum.beds.ac.uk/10.3390/v13101938 - 27 Sep 2021
Viewed by 334
Abstract
Background: The prevalence and prognostic implications of metabolic syndrome (MetS) in patients infected by the SARS-CoV-2 remain unclear. We performed a systematic review and meta-analysis of prevalence and mortality risk in COVID-19 patients with MetS. Methods: Preferred Reporting Items for Systematic Reviews and [...] Read more.
Background: The prevalence and prognostic implications of metabolic syndrome (MetS) in patients infected by the SARS-CoV-2 remain unclear. We performed a systematic review and meta-analysis of prevalence and mortality risk in COVID-19 patients with MetS. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in abstracting data and assessing validity. We searched MEDLINE and Scopus to locate every article published up to 1 September 2021, reporting data on MetS among COVID-19 patients. The pooled prevalence of MetS was calculated using a random effects model and presented using the related 95% confidence interval (CI), while the mortality risk was estimated using the Mantel-Haenszel random effects models with odds ratio (OR) and related 95% CI. Statistical heterogeneity was measured using the Higgins I2 statistic. Results: Six studies, enrolling 209.569 COVID-19 patients [mean age 57.2 years, 114.188 males (54.4%)] met the inclusion criteria and were included in the final analysis. The pooled prevalence of dyslipidaemia was 20.5% of cases (95% CI: 6.7–47.8%, p = 0.03), with high heterogeneity (I2 = 98.9%). Pre-existing MetS was significantly associated with higher risk of short-term mortality (OR: 2.30, 95% CI: 1.52–3.45, p < 0.001), with high heterogeneity (I2 = 89.4%). Meta-regression showed a direct correlation with male gender (p = 0.03), hypertension (p < 0.001), DM (p = 0.01) and hyperlipidaemia (p = 0.04), but no effect when considering age (p = 0.75) and chronic pulmonary disease (p = 0.86) as moderators. Conclusions: MetS represents a major comorbidity in about 20% of COVID-19 patients and it is associated with a 230% increased risk of short-term mortality. Full article
(This article belongs to the Special Issue Metabolic Syndrome and COVID-19)
Show Figures

Figure 1

Back to TopTop